Clinical Trials in Pittsburgh

Showing 11481-11500 of 21,047 trials

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

NCT01485796

The purpose of the study is to acquire additional data on safety and tolerability of recombinant human hyaluronidase (rHuPH20) facilitated subcutaneous treatment of Immune Globulin Infusion (Human), 10% (IGI, 10%) and to assess the mode of product administration. Following a discussion with the FDA at the end of July 2012, all participants still active in the study stopped treatment with rHuPH20 to assure safety of the participants participating in the study and went into a safety follow-up. During this safety follow-up period, participants underwent treatment with the licensed product IGI, 10% (Gammagard Liquid). The intravenous or subcutaneous administration route was at the discretion of the participant and the investigator.

Primary Immunodeficiency Diseases (PID)

Baxalta now part of Shire54 participantsStarted Dec 2011

Irvine, California, United States • Thornton, Colorado, United States • North Palm Beach, Florida, United States +7 more locations

COMPLETEDPhase 2< 1 mile

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis

NCT03394924

A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of EDP-305 in subjects with primary biliary cholangitis

Primary Biliary Cholangitis

Enanta Pharmaceuticals, Inc68 participantsStarted Dec 2017

Dothan, Alabama, United States • Little Rock, Arkansas, United States • Little Rock, Arkansas, United States +83 more locations

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis

Find Trials by Condition in Pittsburgh

Open Label Extension Study of PREOS

An Open-Label Study of Golodirsen in Non-Ambulant Patients With Duchenne Muscular Dystrophy

Carotid Revascularization With ev3 Arterial Technology Evolution (CREATE) Trial

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

A Clinical Trial to Assess the SYNERGY 48 mm Stent System for the Treatment of Atherosclerotic Lesion(s)

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

A Randomized Control Trial of Hip Dislocation Techniques for Pediatric Patients With Cerebral Palsy

GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)

EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)

Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS

Evaluation of Efficacy and Safety of SDN-037

Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID

Gammagard Liquid and rHuPH20 in PID

A Proof of Concept Study of Inhaled Nitric Oxide for Adults With Pulmonary Non-Tuberculous Mycobacterial Infection

A Renal Impairment Study for PF-06651600